Jasper Therapeutics Explores Strategic Alternatives to Maximize Value

Jasper Therapeutics, Inc. announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value. Following an evaluation of current market conditions, the options being considered include a sale of assets, licensing, collaborations, a sale of the company, a business combination, merger, or an orderly wind-down of operations. The company also plans to evaluate cost-saving measures to preserve cash and maintain regulatory compliance, though there is no defined timeline or assurance of a specific outcome from this process.